期刊文献+

吉非替尼敏感性不同的非小细胞肺癌中miRNA-7表达的差异及临床意义 被引量:5

Difference of miRNA-7 expression in the non-small cell lung cancer with different sensitivity to gefitinib and their clinical significance
暂未订购
导出
摘要 目的检测吉非替尼敏感性不同的非小细胞肺癌中miR-7的表达差异,并探讨其临床意义。方法采用吉非替尼(Gefitinib)药物大剂量冲击法诱导H827,建立耐吉非替尼肺癌细胞亚系H827-7/GR,有限稀释法将H827-7/GR细胞单克隆化,CCK-8法检测耐药前后细胞株及各单克隆细胞对吉非替尼的敏感性;RT-PCR方法检测H827、H827-7/GR和耐药单克隆细胞株以及其他对吉非替尼敏感性不同的肺癌细胞株A549、H358、H1299、H1650和H1975中miR-7的表达差异。结果 H827/GR耐药指数大于100;获得的6株耐药单克隆细胞株对吉非替尼的半生长抑制浓度(the half growth inhibition concentration,IC50)值不同;和吉非替尼敏感株H827相比,诱导的耐药细胞株H827/GR、耐药单克隆细胞株和吉非替尼耐药株A549、H358、H1299、H1650和H1975中miR-7的相对表达水平均降低(P<0.05)。结论在非小细胞肺癌中,耐药细胞中miR-7的相对表达水平均较敏感细胞系降低,提示miR-7的低表达可能与非小细胞肺癌耐药性相关,其可能是潜在的肺癌药物敏感性预测分子标志物。 Objective To detect the difference of miRNA-7 expression in the non-small cell lung cancer with different sensitivity to gefitinib and explore their clinical significance. Methods The gefitinib resistant lung cancer cell line H827-7/GR was established from H827 by a method of repeated treatment with high dose of gefifinib for a short period. The H827-7/GR cells were monocloned through the method of limiting dilution. CCK- 8 was used to test the sensitivity of H827, H827-7/GR and the monoclonal cells to gefitinib. RT-PCR was used to detect the difference of miRNA-7 expression in H827, H827-7/GR and the monoclonal ceils, and other lung cancer cell lines with different sensitivity to gefitinib, such as A549, H358, H1299, H1650 and H1975. Results The drug resistance index of H827/GR was larger than 100. The half growth inhibition concentrations ( IC50 ) of the six resistant monoclonal cell lines were different. The miRNA-7 expression of H827/GR, resistant monoelonal cell lines, and gefitinib resistant cell lines such as A549, H358, H1299, H1650 and H1975 were all lower than that of the gefitinib sensitive cell line H827 ( P 〈 0.05 ). Conclusions The miRNA-7 expression of gefitinib resistant cell lines is lower than that of gefitinib sensitive cell lines in the non small cell lung cancer. This suggests that the drug resistance of the non small cell lung cancer may be associated with the low expression of miRNA-7 and it may be a potential molecular marker of the sensitivity of lung cancer to the drugs.
出处 《中国肿瘤外科杂志》 CAS 2015年第2期74-78,共5页 Chinese Journal of Surgical Oncology
基金 国家自然科学基金(81372396) 江苏省自然科学基金(BK20141016)
关键词 吉非替尼 敏感性 microRNA-7 非小细胞肺癌 gefitinib sensitivity miRNA-7 non-small cell lung cancer
  • 相关文献

参考文献15

  • 1Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA: a cancer journal for clinicians, 2014, 64( 1 ) : 9-29.
  • 2Jeong Y, Xie Y, Lee W, et al. Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer [J]. Mol Endocrinal, 2012, 26(8) : 1443-1454.
  • 3潘晶晶,冯继锋.非小细胞肺癌EGFR酪氨酸激酶抑制剂的耐药机制及逆转[J].中国肿瘤外科杂志,2012,4(3):164-168. 被引量:4
  • 4Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function ~J]. Cell, 2004, 116(2) : 281-297.
  • 5Di Leva G, Garofalo M, Croce CM. MieroRNAs in cancer [ J ]. Annu Rev Pathol, 2014, 9: 287-314.
  • 6Rho JK, Choi YJ, Lee JK, et al. Epithelial to mesenchymal tran- sition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line[J]. Lung Cancer, 2009, 63(2) : 219-226.
  • 7Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method [ J ]. Nat Protoc, 2008, 3 (6) : 1101-1108.
  • 8Zhang Z, Wang J, He J, et al. Genetic variants in MUCA gene are associated with lung cancer risk in a Chinese population [ J ~. PloS One, 2013, 8(10) : e77723.
  • 9Lee Y, Ahn C, Han J, et al. ares microRNA processing [ J]The nuclear RNase II1 Drosha initi- Nature, 2003,425(6956) : 415- 419.
  • 10O' Day E, Lal A. MieroRNAs and their target gene networks in breast cancer [J]. Breast Cancer Res, 2010, 12(2) : 201-211.

二级参考文献53

  • 1Olaussen KA, Dubrana K, Damout J, et al. Telomeres and telom- erase as targets for anticancer drug development[ J]. Crit Rev On- col Hematol, 2006, 57 (3) :191-214.
  • 2Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epider- mal growth factor receptor underlying responsiveness of non-small-cell lung cancer to getinib[J]. N Engl J Med, 2034, 350(21) :2129-2139.
  • 3Paez JG, Junne PA, Lee JC, el al. EGFR mutualions in lung cancer:correlation with clinical response to geftinib therapy [ J ]. Science, 2004, 304(5676):1497-1500.
  • 4Mok TS, Wu YL, Yang CH, et al. Gefitinib or earboplatin - pa- elitaxel in pulmonary adenocareinoma[J]. N Engl J Med, 2009, 361 (10) :947-957.
  • 5Fukuoka M, Yano S, Giaecone G, et al. Multi-institutional ran- domized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small cell lung cancer ( the IDEAL 1 Trial ) [ J]. J Clin Oneal, 2003, 21 (12) :2237-2246.
  • 6Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a random- ized trial[ J]. JAMA, 2003, 290(16) :2149-2158.
  • 7Giaeeone G, Herbst RS, Manelgold C, et al. Gefitinib in combi- nation with gemeitabine and eisplatin in advanced non-small-celllung cancer: A phase Ⅲ trial-INTACT 1 [ J]. J Clin Oncol, 2004, 22 ( 5 ) : 777-784.
  • 8Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group: Erlotinib in pre- viously treated non-small-cell lung cancer [J]. N Engl J Med, 2005, 353(2) :123-132.
  • 9Kwake L, Sordellor, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib[J]. Proc Natl Acad Sci USA, 2005, 102(21 ) :7665-7670.
  • 10Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib[ J]. N Engl J Med, 2005, 352(8) :786-792.

共引文献7

同被引文献58

  • 1Zimmermann S,Dziadziuszko R,Peters S. Indications and lim- itations of chemotherapy and targeted agents in non-small- celllung cancerbrain metastases [J]. Cancer Treatment Re- views ,2014,40(6) :716-722.
  • 2Shin HK, Kim MS, Lee JK, et ah Combination effect of ce- tuxim abwith radiation in colorectal cancer cells [J]. Tumori, 2010,96(5) :713-720.
  • 3Lindeman NI,Cagle PT,Beasley MB,et al. Molecular test- ing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors:guideline from the college of american pathologists, international associa- tion for the study of lung cancer,and association for molecular pathology [J]. J Thorac Oncol, 2013,8 (7) : 823- 859.
  • 4Moran C. Importance of molecular features of non-small cell lung cancer for choice of treatment [J]. Am J Pathol, 2011,178(5) : 1940-1948.
  • 5Heon S,Yeap BY,Britt GJ,et al. Development of central nervous system metastases in patients with advanced non- small cell lung cancerand somatic egfrmutations treated with gefitinib or erlotinib [J]. Clin Cancer Res,2010, 16 (23) : 5873-5882.
  • 6Yah DF,Yan SX,Yang JS,et al. Hemrrhage of brain metas- tases from non-small cell lung ca ncer post gefitinib ther- apy:two easereports and review of the literature [J]. BMC Cancer. 2010.10: 49.
  • 7Olmez I,Donahue BR,Butler JS,et al. Clinical outcomes in extraeraniat tumor sites and unusual toxicities with con- current whole brain radiation(WBRT)and Erlotinib treat- ment in Patients with non-small cell lung cancer(NSCLC) with brain metastasis [J]. Lung Cancer,2010,70(2) : 174- 179.
  • 8Yan DF,Yan SX,Yang JS,et al. Hemorrhage of brain metas- tasis from non-small cell lung cancer post gefitinib ther- apy:two case reports and review of the literature [J]. BMC Cancer,2010, 10:49.
  • 9王昆,黄云超.雌激素及其受体与女性非小细胞肺癌[J].国际肿瘤学杂志,2008,35(12):576-578.
  • 10LI JH,TANG R,YING GQ, et al. Investigation of lung cancer in Fuyuan County[J]. Chin J Cancer,2004,13(5):286-289.

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部